Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREDIT feasibility study of 18F-canagliflozin renal distribution in type 2 diabetes
2019-001835-29Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2020
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canagliflozin and 18F-canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by University Medical Center Groningen. Primary endpoints: Dynamic PET data and images, Radiation count measurement and 1 more. Started Nov 2020; status: completed.
02
Drugs
canagliflozin18F-canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-001835-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001835-29.